Get to know the newest ACT Editorial Advisory Board member.
Aaron F. Bartlone, MS, is vice president, preclinical and clinical quality assurance at UCB Pharma, Smyrna, GA. In this role, he leads a global organization of quality professionals based in the United States, Europe, and Japan. Aaron partners with UCB's Development and Medical Affairs organizations to establish robust Quality Systems that ensure GXP compliance while streamlining business processes and maximizing efficiencies. In addition, Aaron's organization executes field surveillance for safety and efficacy studies to ensure trial subjects' safety and rights are protected and that data generated from these studies are accurate and reproducible.
Aaron F. Bartlone, MS, vice president, preclinical and clinical quality assurance, UCB Pharma
Prior to joining UCB, Aaron was head of quality operations-product research & development, with Eli Lilly & Company, Indianapolis, IN, responsible for developing the strategy and framework for Lilly's product research & development quality system.
Aaron's earlier positions with Eli Lilly include European quality director-global product development in Mont-Saint Guibert, Belgium (2001–2004), where he led the delivery of quality assurance services across European drug development sites. Aaron had a staff of quality professionals located in Belgium and Germany, and worked closely with his U.S. counterparts to institute global processes and quality systems commensurate with international regulations and industry-best practices.
Prior to working at Lilly's Mont-Saint Guibert, Belgium, location, Aaron held numerous positions with Lilly in Indianapolis, IN: quality control manager-global product development (1999–2001); head of quality-biotechnology quality control and quality control laboratories (1998–1999); quality control team leader-oral and parenteral clinical products (1997–1998); senior compliance auditor-corporate quality assurance (1996–1997); and laboratory group leader-quality control laboratories (1994–1996).
From 1992 to 1995, Aaron was an associate professor at Ivy Tech State College, Indianapolis, IN, where he taught chemistry, physics, and mathematics, and participated in the design of a new laboratory teaching facility. Earlier, he was a clinical toxicologist with South Bend Medical Foundation, South Bend, IN, performing laboratory procedures for substances of abuse and forensic investigations.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.